Multi-cohort study links three brain pathways to lasting response to DBS for depression
Mount Sinai-led researchers found that sustained improvement after subcallosal cingulate deep brain stimulation tracked with stimulation of three white matter tracts.
A team led by Mount Sinai researchers pooled data from several cohorts, including the BROADEN trial and groups at the University of Toronto and Emory, in what they call the largest analysis to date of subcallosal cingulate deep brain stimulation for treatment-resistant depression. Published October 1 in the American Journal of Psychiatry and announced October 13, the study found that lasting improvement was associated with stimulating three white matter pathways: the cingulum bundle, the forceps minor and the medial uncinate fasciculus/ventral amygdalofugal pathway. People who had not responded after two years lacked engagement of the left cingulum bundle.
The work supports connectome-guided electrode placement, an approach used in Abbott’s ongoing TRANSCEND trial. Caveats: much of the analysis relied on generic connectivity maps, the team did not test repositioning electrodes, and several authors have financial ties to Abbott.
Learn more: Deep brain stimulation · Abbott Neuromodulation